Novartis Ag (NVS) Change in Cash (2009 - 2026)
Novartis Ag (NVS) posted Change in Cash of $757.0 million for Q2 2026, up 195.58% sequentially from -$792.0 million in Q2 2025, and up 195.58% YoY from $256.1 million in Q2 2025.
Novartis Ag (NVS) Change in Cash (2009 - 2026) Analysis & Trends
Novartis Ag has reported Change in Cash for 18 years, with the latest figure at $757.0 million in Q2 2026.
- Quarterly Change in Cash rose 195.58% year-over-year to $757.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $165.0 million (up 107.77% YoY) and the FY2025 annual result came in at -$600.0 million, up 68.98% from the prior year.
- Change in Cash grew to $757.0 million in Q2 2026 per NVS's latest filing, from -$792.0 million in the prior quarter.
- Over five years, Change in Cash peaked at $5.5 billion in Q3 2024 and troughed at -$10.2 billion in Q2 2022.
- A 5-year average of -$1.6 billion and a median of -$953.0 million in 2023 frame the typical range for Change in Cash.
- The sharpest annual moves came in 2024 and 2026: Change in Cash slumped 3061.11% in 2024, then soared 195.58% in 2026.
- Over 5 years, Change in Cash stood at -$10.2 billion in 2022, then jumped by 101.77% to $180.0 million in 2023, then plunged by 3061.11% to -$5.3 billion in 2024, then jumped by 85.14% to -$792.0 million in 2025, then jumped by 195.58% to $757.0 million in 2026.
- According to Business Quant data, Change in Cash over the past three periods registered $757.0 million, -$792.0 million, and -$5.3 billion for Q2 2026, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -1.27 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -2.82 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.49 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 739.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.95 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -4.45 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -727.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -14.32 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 757.00 Mn |
| Jun 30, 2025 | -792.00 Mn |
| Dec 31, 2024 | -5.33 Bn |
| Sep 30, 2024 | 5.53 Bn |
| Jun 30, 2024 | -1.53 Bn |
| Dec 31, 2023 | 180.00 Mn |
| Jun 30, 2023 | -1.11 Bn |
| Jun 30, 2022 | -10.18 Bn |
| Jun 30, 2021 | 1.29 Bn |
| Dec 31, 2020 | 498.00 Mn |
| Jun 30, 2020 | 1.35 Bn |
| Jun 30, 2019 | 2.61 Bn |
| Mar 31, 2019 | 994.00 Mn |
| Dec 31, 2018 | -716.00 Mn |
| Jun 30, 2018 | 6.74 Bn |
| Dec 31, 2017 | 50.00 Mn |
| Sep 30, 2017 | 954.00 Mn |
| Jun 30, 2017 | 284.00 Mn |
| Mar 31, 2017 | 565.00 Mn |
| Dec 31, 2016 | 362.00 Mn |